#United States #Salt Lake City #Co-Diagnostics #PCR Technology #WHX Kuala Lumpur

Co-Diagnostics, Inc. to Host Booth at WHX Kuala Lumpur 2025

Co-Diagnostics, Inc. (Nasdaq-CM: CODX), a leader in molecular diagnostics, has announced its participation in the World Health Expo (WHX) taking place in Kuala Lumpur from July 16 to 18, 2025. The event, hosted at the Malaysia International Trade and Exhibition Centre (MITEC), is recognized as the foremost healthcare exhibition across Southeast Asia. With an expected attendance of over 10,000 visitors from more than 54 countries, WHX offers a premier platform for industry professionals to network, share insights, and explore the latest in healthcare innovations.

This year, Co-Diagnostics aims to significantly enhance awareness of its cutting-edge suite of PCR (polymerase chain reaction) in vitro diagnostic tools designed for the detection of infectious diseases. At Booth L18, attendees will have the opportunity to learn about Co-Diagnostics' proprietary Co-Primers® technology and its forthcoming Co-Dx™ PCR platform. Among the key products showcased will be the Co-Dx PCR MTB test and the eight-plex Co-Dx HPV test, both of which are on schedule for clinical evaluations later this year.

The WHX event, formerly known as Asia Health/Medlab Asia, is dedicated to bringing together leading industry and healthcare professionals to discuss technological advancements and forthcoming trends. The exhibition is pivotal for fostering collaboration within the global healthcare community, and Co-Diagnostics’ participation underscores its commitment to leading innovation in molecular diagnostics.

The decision for Co-Diagnostics to exhibit at WHX has been facilitated by a grant from World Trade Center Utah. As an organization dedicated to broadening the international reach of Utah companies, World Trade Center Utah endeavors to boost revenue through expanding international sales, attracting foreign investments, and creating global partnerships. This grant emphasizes the potential for Utah-based companies, such as Co-Diagnostics, to gain visibility and recognition on an international stage.

Co-Diagnostics, headquartered in Salt Lake City, Utah, utilizes state-of-the-art methodologies to develop, manufacture, and market advanced diagnostic technologies. Their diagnostic tests capitalize on nucleic acid detection and analysis, allowing healthcare providers to effectively identify and manage infectious diseases. The company is also at the forefront of designing tests for its Co-Dx PCR at-home and point-of-care platforms, exploring genetic markers across various applications.

As WHX Kuala Lumpur approaches, Co-Diagnostics is eager to present its innovative products and engage with healthcare professionals eager to learn about the latest advancements in the industry. The company encourages all attendees to visit Booth L18 to discover its complete range of products and discuss the potential for improving patient outcomes through state-of-the-art diagnostic solutions.

For more information about the WHX event or Co-Diagnostics, attendees are urged to visit their booth and explore the exciting possibilities of collaboration and innovation within the molecular diagnostics field.

Note: The Co-Dx PCR platform and its associated tests are pending regulatory review by the FDA and other governing bodies and are therefore not currently available for sale.